Phase 1 KRAS G12D Mutation Clinical Trials
3 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–3 of 3 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Advanced Solid CancerKRAS G12D Mutation
Arvinas Inc.159 enrolled14 locationsNCT07023731
Recruiting
Phase 1Phase 2
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Advanced Solid TumorsKRAS G12D Mutations
Genfleet Therapeutics (Shanghai) Inc.407 enrolled20 locationsNCT06500676
Recruiting
Phase 1Phase 2
A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd.152 enrolled6 locationsNCT06667544